Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in Japan

Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in Japan - Additional effects of SFC in patients with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003403

Enrollment

1008

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Add on treatment with inhaled 250mcg dose of SFC (twice daily), everyday, for 3years control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD

Exclusion criteria

Exclusion criteria: 1. other respiratory diseases 2. regular use of inhaled corticosteroids 3. regular use of inhaled and transdermal beta2 agonists 4. severe other orgen diseases 5. active malignancies

Design outcomes

Primary

Measure	Time frame
Prevent the numbers and severity of exacerbation/yr/patient	—

Secondary

Measure	Time frame
Prevent the decline of FEV1	—

Countries

Japan

Contacts

Public ContactKazako Matsunaga

Kurume University School of Medicine Department of Medicine, Division of Respirology, Neurology, and Rheumatology

kmatsunaga@med.kurume-u.ac.jp0942-31-7560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026